E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion
| Status: | Recruiting |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 49 |
| Updated: | 4/21/2016 |
| Start Date: | October 2015 |
| End Date: | October 2016 |
| Contact: | Katie Sy |
| Email: | Katrina.Sy@cshs.org |
| Phone: | 3102487641 |
E-cigarettes deliver nicotine by creating an aerosol of ultrafine particles. Many questions
remain about the size and composition and especially about the potential toxicity of these
particles. Thus, a key unanswered question—and the research question proposed—is whether
e-cigarette aerosol triggers the same acute impairment in coronary microvessel function as
does conventional cigarette smoke, which delivers a very well-defined exposure to fine
particles and many fold greater exposure to toxic (combustion) products including volatile
organic compounds (such as acrolein) that have been implicated in the pathogenesis of
tobacco-related coronary disease.
Because the effects of nicotine on the human coronary microcirculation remain incompletely
defined—with multiple potential vasodilator and vasoconstrictor actions each of which may
vary by dose—we will determine the comparative effects of conventional cigarette smoke
against e-cigarette aerosol with no nicotine, with low-dose nicotine, and with high-dose
nicotine.
remain about the size and composition and especially about the potential toxicity of these
particles. Thus, a key unanswered question—and the research question proposed—is whether
e-cigarette aerosol triggers the same acute impairment in coronary microvessel function as
does conventional cigarette smoke, which delivers a very well-defined exposure to fine
particles and many fold greater exposure to toxic (combustion) products including volatile
organic compounds (such as acrolein) that have been implicated in the pathogenesis of
tobacco-related coronary disease.
Because the effects of nicotine on the human coronary microcirculation remain incompletely
defined—with multiple potential vasodilator and vasoconstrictor actions each of which may
vary by dose—we will determine the comparative effects of conventional cigarette smoke
against e-cigarette aerosol with no nicotine, with low-dose nicotine, and with high-dose
nicotine.
Inclusion Criteria:
- Age 18-49
- Regular cigarette smoker defined as at least 1 pack year and ≥ 5/day
- E-cigarette smoker defined as ≥ 1/week in the last 6 months.
Exclusion Criteria:
- Sub-optimal echocardiography images as determined by the sonographer and/or
investigators.
- History of cardiopulmonary (including asthma or use of inhalers),
- History of diabetes or dyslipidemia
- History of psychiatric illness
- Blood Pressure > 140/90
- Body Mass Index ≤ 18.5 or ≥ 30 kg•m2
- Evidence of any of the above by physical examination, Electrocardiogram (ECG) or
echocardiogram
- Resting Heart Rate > 100 beats/min
- Cardiac rhythm disorder, specifically: rhythm other than sinus, Supraventricular
Tachycardia (SVT), atrial fibrillation, ventricular tachycardia
- Use of prescription medication except oral contraceptive pills
- History of illicit drug use (self-stated)
- Pregnant
- Any other condition(s) deemed by the physician investigators that put subjects at
risk for participating in the study
We found this trial at
1
site
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Ronald G Victor, MD
Phone: 310-248-7641
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
